Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...

Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...

Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

A Johnson & Johnson unit working to resolve massive cancer litigation in bankruptcy court was accused by a former head of the ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...